Updates in Hospice and Palliative Medicine and Intensive Physician Board Review Course 2022 - Online Access to syllabus/video presentations only

---

ONLINE

Tuesday, September 20, 2022, 8:00 AM - Thursday, September 22, 2022, 5:30 PM

This Board Review Course will allow physicians, fellows and advanced nurse practitioners will gain the knowledge and competence pertaining to symptom and pain management, issues facing patients at end-of- life, and effective communication techniques to implement into clinical practice.

1. Interpret spiritual, legal and medical issues facing patients at end-of-life.
2. Provide optimal end-of-life care including symptom management, psychosocial support and state of the art pain management.
3. Demonstrate effective communication techniques with patients in the advanced stages of cancer or debilitating disease and provide quality end-of-life care.

 Updates in Hospice and Palliative Medicine and Intensive Physician Board Review Course - September 20-22, 2022

 Online Access to syllabus/video presentations only $499.00 (will be available 5 days after the conference)

 

Online Access Registration Fee - includes online course materials (PowerPoint Presentation Slides, Recorded Talks, Q&A Study Bank, ABIM Blueprint)

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

 

The registration form for this activity is currently unavailable.

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.